SCM
PACB icon

Sterling Capital Management’s Pacific Biosciences PACB Stock Holding History

Sterling Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.19K Sell
1,306
-7,897
-86% -$11.5K ﹤0.01% 2971
2026
Q1 		$12.1K Sell
9,203
-6,713
-42% -$12K ﹤0.01% 2274
2025
Q4 		$29.8K Sell
15,916
-3,137
-16% -$6.03K ﹤0.01% 2023
2025
Q3 		$24.4K Buy
19,053
+11,722
+160% +$15.9K ﹤0.01% 2050
2025
Q2 		$9.09K Buy
7,331
+2,611
+55% +$3.02K ﹤0.01% 2187
2025
Q1 		$5.57K Sell
4,720
-4,042
-46% -$6.2K ﹤0.01% 2110
2024
Q4 		$16K Buy
8,762
+7,800
+811% +$15.2K ﹤0.01% 1946
2024
Q3 		$1.64K Buy
+962
New +$1.58K ﹤0.01% 2279

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sterling Capital Management's PACB Position: Q2 2026 in Review

Sterling Capital Management reduced its Pacific Biosciences (PACB) stake by 86% in Q2 2026, selling an estimated $11.5K and leaving 1,306 shares worth $2.19K. The position accounts for ﹤0.01% of the portfolio, ranked #2971.

Sterling Capital Management first reported a position in PACB in Q3 2024 and has held it in 8 quarters since. The position peaked at $29.8K in Q4 2025. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Sterling Capital Management held 1,306 shares of Pacific Biosciences worth $2.19K as of Q2 2026.
  • Sterling Capital Management sold 7,897 Pacific Biosciences shares in Q2 2026, an estimated $11.5K.
  • Pacific Biosciences made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2971 holding.
  • Sterling Capital Management first reported a position in Pacific Biosciences in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Pacific Biosciences position peaked at $29.8K in Q4 2025.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.